Breaks Categories: News

WednesdayAug 14, 2024 1:55 pm

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL), Progressive Care (RXMD) Release Q2 2024 Financial Results Showing 474% Revenue Increase

NextPlat (NASDAQ: NXPL), a global e-Commerce provider, has released record financial results for its second fiscal quarter, the period ended June 30, 2024; the results include the consolidation of the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD). Highlights of the report indicate the company experienced a 474% increase in consolidated Q2 revenues, which totaled $17 million, and a record 34.2% quarterly margins; the report noted that the company anticipates reaching $70 million in 2024 annual revenues with additional healthcare services contracts and E-commerce expansion expected to drive the company’s continued growth. “We are…

Continue Reading

WednesdayAug 14, 2024 9:00 am

BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports Concussion Drug Stable Across Wide Range of Temps

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, recently completed the synthesis of its ONP-002 drug batch for its upcoming planned phase 2 clinical trial. Consequently, the company is reporting that ONP-002, its lead candidate for treating concussion, is stable across a wide temperature range, thus eliminating the need for cumbersome cold storage during transport and storage. Specifically, the company reported three-month stability with more than 99% purity at temperatures ranging from -20°C to 104°C. “We understand the importance of getting ONP-002 into the brain quickly after concussive injury to…

Continue Reading

TuesdayAug 13, 2024 10:13 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the signing of a definitive Loan Restructuring Agreement with the European Investment Bank (“EIB”), its lender. The agreement also included an amendment and restatement to the Finance Contract between the parties. According to the announcement, an amount equal to approximately €26.6 million (approximately $29 million), including interest accrued to date, owned by Scinai to EIB under the finance contract, will be converted into 1,000 preferred shares, no par value per share, of…

Continue Reading

MondayAug 12, 2024 10:57 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Partners with RxSpark to Provide Integrated Solution for Medication Management

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced a strategic partnership with RxSpark, a platform dedicated to providing affordable prescription medications and healthcare services. According to the announcement, this partnership will enhance the patient’s experience by integrating HealthLynked’s advanced healthcare network with RxSpark’s pharmacy discounts and prescription price comparison tool. Through this exciting integration, HealthLynked members can find savings of up to 90% off their medications, easily manage their prescriptions, and ensure timely access to necessary medications. Key benefits include enhanced prescription management, improved access to affordable medications, streamlined healthcare experience, and cost savings for patients. “At HealthLynked,…

Continue Reading

ThursdayAug 08, 2024 2:00 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new preclinical data regarding buntanetap, its lead compound. According to the report, the date demonstrates the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease. The announcement noted that the Alzheimer’s Disease Diagnostics and Therapeutics Market size is projected to reach $7.7 billion this year and grow to $10.1 billion by 2029. Major factors contributing to that growth include the increasing use…

Continue Reading

ThursdayAug 08, 2024 1:32 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, was featured in the latest episode of the BioMedWire Podcast, which is part of a sustained effort by IBN (Investor Brand Network) to provide specialized content distribution via widespread syndication channels. During the episode, Clene CEO and president Rob Etherington talks with IBN’s Carmel Fisher about the company’s mission, including its novel approach to the treatment of diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene Inc. is focused entirely on improving mitochondrial health and protecting…

Continue Reading

WednesdayAug 07, 2024 3:30 pm

BioMedNewsBreaks — Scorpius Holdings Inc. (NYSE American: SCPX) Releases Public Offering Pricing for Public Offering

Scorpius Holdings (NYSE American: SCPX), an integrated contract-development and manufacturing organization (CDMO), has announced the pricing of an underwritten public offering. The offering is comprised of 12,500,000 shares of common stock or prefunded warrants. Each share of common stock or prefunded warrant is offered at $1. According to the announcement, the company has estimated gross proceeds of approximately $12,500,000, before underwriting discounts and offering expenses are deducted; the proceeds will be used for working capital and general corporate expenses. The company also granted the underwriters a 45-day option to purchase up to 1,875,000 additional shares of common stock and/or prefunded…

Continue Reading

WednesdayAug 07, 2024 12:33 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), today released its Q2 2024 financial results. In addition, the company provided recent updates on its CNM-Au8(R) programs evaluating the use of CNM-Au8 for the treatment of ALS and Rett Syndrome. “We are approaching our next FDA interaction focused on the regulatory path forward to potentially bring CNM-Au8 to people living with ALS,” commented Rob Etherington, President and…

Continue Reading

WednesdayAug 07, 2024 10:42 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has released preclinical data from a study of its lead compound, buntanetap. According to the announcement, the study showed the synergistic effect of buntanetap combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity[R]) in enhancing cognition in a mouse model of Alzheimer’s disease. The news comes as the global Alzheimer’s Disease Therapeutics Market is experiencing significant growth as an escalating aging population along with earlier and more accurate diagnoses contribute to more people facing the disease.…

Continue Reading

TuesdayAug 06, 2024 12:49 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA

Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial health and neuronal function to treat neurodegenerative diseases, and its wholly owned subsidiary Clene Nanomedicine Inc., have submitted new data to the U.S. Food and Drug Administration (“FDA”). The data is regarding CNM-Au8(R) biomarker and clinical efficacy information, including post hoc analyses from two phase 2 clinical trials of CNM-Au8 for the treatment of ALS; the trials were conducted independently. According to the announcement, this new data is in addition to original data the company has discussed with FDA and is intended to guide the planned FDA Type C interaction; that…

Continue Reading